Fig. 1

Serum TWEAK levels in patients with PsoA (n = 13) and controls (n = 57). Serum samples have been collected at baseline and 12 and 24 weeks after the initiation of etanercept therapy. TWEAK levels have been evaluated with a commercially available ELISA kit. a Median is indicated for each group as a black line in the box. b Evolution over time of TWEAK levels is represented for each patient